Study of EBV-positive T/NK-cell lymphoma and related diseases
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a new diagnosis of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease, such as extranodal NK/T-cell lymphoma or aggressive NK-cell leukemia.
- For the retrospective part: your diagnosis must have been made between January 1, 2017 and December 31, 2025 at a participating center. You must have medical records with important details about your diagnosis, staging, and treatment.
- For the prospective part: your diagnosis must be made between June 1, 2026 and December 31, 2030. You must agree to provide a blood sample at the start and to follow the study's regular check-up schedule.
- You cannot be in the retrospective part if we don't have enough follow-up information to know how you are doing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This study looks at whether a simple blood test can find signs of the Epstein-Barr virus (EBV) that may help doctors better understand your lymphoma. It aims to see if this blood test can be useful in monitoring the disease.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.